A small molecule p75(NTR) ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice

作者：Simmons Danielle A^*; Belichenko Nadia P; Ford Ellen C; Semaan Sarah; Monbureau Marie; Aiyaswamy Sruti; Holman Cameron M; Condon Christina; Shamloo Mehrdad; Massa Stephen M; Longo Frank M

来源：Human Molecular Genetics, 2016, 25(22): 4920-4938.

DOI：10.1093/hmg/ddw316

Decreases in the ratio of neurotrophic versus neurodegenerative signalling play a critical role in Huntington's disease (HD) pathogenesis and recent evidence suggests that the p75 neurotrophin receptor (NTR) contributes significantly to disease progression. p75(NTR) signalling intermediates substantially overlap with those promoting neuronal survival and synapse integrity and with those affected by the mutant huntingtin (muHtt) protein. MuHtt increases p75(NTR)-associated deleterious signalling and decreases survival signalling suggesting that p75(NTR) could be a valuable therapeutic target. This hypothesis was investigated by examining the effects of an orally bioavailable, small molecule p75(NTR) ligand, LM11A-31, on HD-related neuropathology in HD mouse models (R6/2, BACHD). LM11A-31 restored striatal AKT and other pro-survival signalling while inhibiting c-Jun kinase (JNK) and other degenerative signalling. Normalizing p75(NTR) signalling with LM11A-31 was accompanied by reduced Htt aggregates and striatal cholinergic interneuron degeneration as well as extended survival in R6/2 mice. The p75(NTR) ligand also decreased inflammation, increased striatal and hippocampal dendritic spine density, and improved motor performance and cognition in R6/2 and BACHD mice. These results support small molecule modulation of p75(NTR) as an effective HD therapeutic strategy. LM11A-31 has successfully completed Phase I safety and pharmacokinetic clinical trials and is therefore a viable candidate for clinical studies in HD.

• 出版日期2016-11-15